Cargando…
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER
BACKGROUND: Statins and metformin are commonly prescribed for patients, including those with prostate cancer. Preclinical and epidemiologic studies of each agent have suggested anti-cancer properties. METHODS: Patient data from three randomised, double-blind, placebo-controlled, phase III studies ev...
Autores principales: | Joshua, Anthony M., Armstrong, Andrew, Crumbaker, Megan, Scher, Howard I., de Bono, Johann, Tombal, Bertrand, Hussain, Maha, Sternberg, Cora N., Gillessen, Silke, Carles, Joan, Fizazi, Karim, Lin, Ping, Duggan, William, Sugg, Jennifer, Russell, David, Beer, Tomasz M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394474/ https://www.ncbi.nlm.nih.gov/pubmed/35643841 http://dx.doi.org/10.1016/j.ejca.2022.04.005 |
Ejemplares similares
-
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials
por: Armstrong, Andrew J., et al.
Publicado: (2019) -
Enzalutamide in European and North American men participating in the AFFIRM trial
por: Merseburger, Axel S, et al.
Publicado: (2015) -
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
por: Zhao, Jimmy L., et al.
Publicado: (2022) -
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
por: Suzuki, Hiroyoshi, et al.
Publicado: (2021) -
Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials
por: Saad, F, et al.
Publicado: (2017)